Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E16.77 EPS (ttm)17.46 Insider Own0.29% Shs Outstand216.92M Perf Week-2.20%
Market Cap63.51B Forward P/E11.09 EPS next Y26.39 Insider Trans3.74% Shs Float210.86M Perf Month-15.50%
Income3.71B PEG2.34 EPS next Q5.91 Inst Own91.60% Short Float1.58% Perf Quarter-5.27%
Sales12.27B P/S5.17 EPS this Y3.00% Inst Trans0.12% Short Ratio2.39 Perf Half Y3.59%
Book/sh59.66 P/B4.91 EPS next Y6.13% ROA11.30% Target Price381.18 Perf Year2.82%
Cash/sh17.01 P/C17.22 EPS next 5Y7.18% ROE20.90% 52W Range244.28 - 370.57 Perf YTD-8.10%
Dividend- P/FCF14.33 EPS past 5Y24.80% ROI21.90% 52W High-20.99% Beta0.86
Dividend %- Quick Ratio2.10 Sales past 5Y17.30% Gross Margin86.70% 52W Low19.85% ATR10.69
Employees7300 Current Ratio2.30 Sales Q/Q15.10% Oper. Margin43.50% RSI (14)34.63 Volatility2.66% 3.67%
OptionableYes Debt/Eq0.47 EPS Q/Q38.50% Profit Margin20.70% Rel Volume1.82 Prev Close284.81
ShortableYes LT Debt/Eq0.47 EarningsJan 25 BMO Payout0.00% Avg Volume1.39M Price292.78
Recom2.00 SMA20-9.44% SMA50-11.02% SMA200-3.43% Volume2,531,820 Change2.80%
Feb-16-18Downgrade Argus Buy → Hold
Feb-05-18Reiterated Mizuho Buy $400 → $433
Jan-26-18Reiterated H.C. Wainwright Buy $340 → $363
Jan-24-18Reiterated Canaccord Genuity Hold $340 → $350
Jan-17-18Reiterated Canaccord Genuity Hold $340 → $350
Dec-22-17Reiterated Nomura Buy $355 → $420
Dec-20-17Upgrade Credit Suisse Neutral → Outperform
Oct-27-17Initiated Canaccord Genuity Hold $340
Oct-25-17Reiterated RBC Capital Mkts Sector Perform $315 → $313
Oct-24-17Initiated Guggenheim Buy $402
Oct-23-17Resumed Piper Jaffray Overweight $390
Oct-23-17Downgrade Citigroup Buy → Neutral
Oct-17-17Upgrade Stifel Hold → Buy $300 → $415
Oct-17-17Upgrade Mizuho Neutral → Buy $319 → $400
Oct-05-17Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-21-17Downgrade Raymond James Strong Buy → Mkt Perform
Sep-20-17Initiated SunTrust Buy $360
Sep-15-17Initiated RBC Capital Mkts Sector Perform $319
Jul-26-17Upgrade Goldman Neutral → Buy
Jul-11-17Resumed Jefferies Hold
Feb-23-18 06:04AM  Better Buy: Biogen Inc. vs. Celgene Corporation Motley Fool
Feb-22-18 08:30AM  What's in the Cards for Ionis (IONS) This Earnings Season? Zacks
Feb-21-18 12:49PM  Biotech Alkermes May Surge On Wave of New Drugs Investopedia
Feb-20-18 11:33PM  [$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimers Trial The Wall Street Journal
08:45AM  Alkermes Sets Itself Up for a "Transformative" 2018 Motley Fool
04:28AM  [$$] Biogen CEO Calls Share Slump an Overreaction to Alzheimer's Trial The Wall Street Journal
Feb-19-18 07:32AM  Buy Biogen Stock on the Dip? Motley Fool
Feb-18-18 12:50PM  Biogens key Alzheimers disease drug is facing potential signs of trouble MarketWatch
Feb-16-18 11:28AM  How Biogen Inc (NASDAQ:BIIB) Delivered A Better ROE Than Its Industry Simply Wall St.
09:37AM  Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs Benzinga
07:17AM  FDA Sets the Stage for Earlier-Stage Alzheimer's Treatments Zacks
Feb-15-18 06:27PM  U.S. FDA looks to pave way for earlier-stage Alzheimer's drugs Reuters
05:11PM  Why Biogen May Seek A Merger In The Wake Of Alzheimer's Worries Investor's Business Daily
04:33PM  Biogens key Alzheimers disease drug is facing potential signs of trouble MarketWatch
03:01PM  Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates Zacks
Feb-14-18 07:05PM  Biogen shares plunge after company makes change to Alzheimers drug trials American City Business Journals -6.60%
05:01PM  The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy Business Wire
05:01PM  Getting technical: Trading the Chipotle taco-transition gap Yahoo Finance Video
04:33PM  Why Biogen, Groupon, and Omeros Slumped Today Motley Fool
04:09PM  Dow's Merck Failed On Alzheimer Drug But It Shouldn't Hurt Biogen Investor's Business Daily
03:51PM  Here's Why Alkermes Spiked Today Motley Fool
09:47AM  Merck (MRK) Halts Another Late Stage Study on Alzheimer's Zacks
Feb-12-18 12:40PM  Richard Pzena's Top 5 New Buys of the 4th Quarter GuruFocus.com
05:08AM  Norway to buy Biogen's Spinraza medicine - broadcaster NRK Reuters
Feb-10-18 02:33PM  3 ETFs to Watch on Biotech Earnings Zacks
10:33AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-09-18 09:05AM  The Zacks Analyst Blog Highlights: Novartis, BP and Biogen Zacks
Feb-08-18 03:23PM  Top Research Reports for Novartis, BP & Biogen Zacks
11:16AM  Biogen Halts Tysabri Development in Stroke as Study Fails Zacks
09:41AM  The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease Benzinga
Feb-07-18 05:02PM  What Should We Expect From Biogen Incs (NASDAQ:BIIB) Earnings Over The Next Year? Simply Wall St.
04:53PM  Biogen's Tysabri Fails In Stroke Trial Coming As 'No Surprise' Investor's Business Daily
09:41AM  Biogen stops testing Tysabri to treat stroke after study fails Reuters
07:43AM  Biogen stops developing Tysabri to treat stroke after failed study Reuters
07:40AM  Biogen stock declines after stroke trial failure MarketWatch
07:30AM  Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke Business Wire
Feb-05-18 04:01PM  Biogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference Business Wire
10:45AM  Why Biogen Stock Can Continue To Rise Investopedia
08:49AM  Billionaire Fund Managers Are Bullish On These Biotech Stocks Insider Monkey
07:35AM  Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-02-18 04:30PM  Biotech stocks hold up amid market sell-off CNBC Videos
Feb-01-18 05:48PM  Biogen Inc (BIIB) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Jan-31-18 07:13PM  Cramer Remix: Here are the best-in-show biotechs for 2018... CNBC Videos
07:00PM  Cramer Remix: AbbVie and Biogen are the best-in-show biotechs for 2018 so far CNBC
12:53PM  Biogen Spin-Off Bioverativ To Be Acquired Forbes
09:29AM  UBS: Buy Biogen For Pipeline, M&A Potential Benzinga
Jan-29-18 03:28PM  Biogen Inc. Caps Off a Solid 2017, Waits on Aducanumab Motley Fool
Jan-27-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-26-18 08:42AM  Biotechnology Movers: Karyopharm And Synergy Market Exclusive
06:00AM  Biogen's Breakout Seen Boosting Stock 13% Investopedia
Jan-25-18 04:47PM  With drug company M&A running high, $119M Redwood City biotech IPO surges 69% American City Business Journals
04:33PM  US STOCKS-Dow and S&P 500 reach records; market cools after Trump talks up dollar Reuters
02:52PM  US STOCKS-Wall St surrenders gains after Trump talks up dollar Reuters
02:43PM  Biogen: Where Is That Blockbuster Acquisition? Forbes
12:55PM  US STOCKS-Robust earnings, weak dollar lift Wall Street Reuters
12:44PM  Biogen buys a brain disorder drug for $217 million, but needs to go bigger, analyst says CNBC
12:09PM  Biogen's Spinraza: Great Launch, Rough Ride Bloomberg
11:27AM  Biogen forecasts robust 2018 as Spinraza sales surge Reuters
11:07AM  Biogen (BIIB) Q4 Earnings Miss, Sales Top, 2018 View Upbeat Zacks
10:48AM  US STOCKS-Wall St advance loses steam as Caterpillar reverses Reuters
10:44AM  Biotech Earnings: Celgene Slides, Biogen Gains in Sector Stalemate Barrons.com
09:55AM  US STOCKS-Wall Street gains on solid earnings, dollar drop Reuters
09:35AM  How Does Biogen Make its Money? Investopedia
09:11AM  Benzinga Pro's 4 Stocks To Watch Today Benzinga
09:06AM  US STOCKS-Wall Street to open higher on solid earnings, dollar drop Reuters
09:01AM  Biogen forecasts robust 2018, quarterly revenue beats on Spinraza sales Reuters
08:21AM  Biogen (BIIB) Q4 Earnings Miss, Sales Top, Stock Up Zacks
07:09AM  Biogen shares surge after Q4 revenue beat, upbeat guidance MarketWatch
06:40AM  Biogen posts fourth-quarter loss on income tax charge Reuters
06:29AM  Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively Business Wire
Jan-24-18 09:00AM  Will Sanofi's Big Hemophilia Deal Pay Off? Motley Fool
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
01:34AM  Earnings Preview: What To Expect From Biogen On Thursday Forbes
Jan-22-18 04:12PM  Celgene Will Buy Juno Therapeutics For $9 Billion; Sanofi Acquires Bioverativ Investor's Business Daily
11:43AM  Is Sanofis Bioverative Inc Buyout Just the Start? InvestorPlace
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
09:25AM  What's in the Cards for Biogen (BIIB) This Earnings Season? Zacks
08:17AM  Whom Will Pfizer Buy in 2018? Motley Fool
08:00AM  Why Bioverativ Inc. Stock Is Soaring Today Motley Fool
07:30AM  Blog Exposure - Acorda Therapeutics Stock Surges Amidst Rumors Of Takeover ACCESSWIRE
06:00AM  3 Biotech Stocks on the Verge of Major Breakouts Investopedia
05:43AM  Bioverativ Inc Stock Gets 64% Premium in Acquisition by Sanofi InvestorPlace
Jan-19-18 04:53PM  This Biotech Stock Rocketed 15% On Rumors Biogen Could Buy It Investor's Business Daily
11:57AM  Here's Why Acorda Therapeutics Inc. Stock Is Surging Today Motley Fool
Jan-18-18 04:00PM  Merck & Co.s Quarterly Revenue Trend Market Realist
09:54AM  Biogen, Pfizer vets launch autoimmune disease startup backed by $58M American City Business Journals
03:00AM  Stocks With Rising Relative Strength: Biogen Investor's Business Daily
Jan-16-18 08:03AM  See what the IHS Markit Score report has to say about Biogen Inc. Markit
Jan-14-18 08:18AM  Will 2018 Be Biogen Inc.'s Best Year Yet? Motley Fool
Jan-13-18 03:33PM  Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet? Motley Fool
Jan-12-18 01:33PM  Top Stock Reports for Home Depot, CVS Health & Biogen Zacks
Jan-11-18 10:33AM  Developments for Ionis Pharmaceuticals Post-3Q17 Market Realist
03:00AM  Biogen Trying To Close In On Key Technical Measure Investor's Business Daily
Jan-10-18 06:25PM  How will tax reform affect Biogen? Its CFO offered a few hints at J.P. Morgan American City Business Journals
04:10PM  Exploring Ioniss 3Q17 Quarterly Revenue Trend Market Realist
02:35PM  A Look at Ionis Pharmaceuticals January 2018 Valuation Market Realist
10:43AM  Bayer and J&J win big, Microsoft lags because of Intel, Apple turns over information Yahoo Finance Video
10:33AM  Analysts Recommendations for Incyte in January 2018 Market Realist
09:04AM  Incytes Collaborations and Developments in 4Q17 Market Realist
Jan-09-18 10:36AM  Biogen: S&P 500s Top Loser on January 8 Market Realist
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredEVP, Chief Medical OfficerFeb 20Sale292.00743216,9566,553Feb 21 04:10 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,354010,233Feb 20 04:27 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,33909,186Feb 20 04:25 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,47204,854Feb 20 04:23 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,71205,407Feb 20 04:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 15Option Exercise0.0016104,600Feb 20 04:18 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecFeb 15Option Exercise0.001,712023,970Feb 20 04:17 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Sale298.851,294386,7127,296Feb 20 08:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.002,01208,565Feb 14 06:37 PM
PANGIA ROBERT WDirectorJan 09Option Exercise57.835,832337,26523,539Jan 10 05:28 PM
PANGIA ROBERT WDirectorJan 09Sale329.655,8321,922,51917,707Jan 10 05:28 PM
Vounatsos MichelChief Executive OfficerDec 29Buy320.55780250,0294,879Jan 02 04:21 PM
DENNER ALEXANDER JDirectorNov 29Buy319.8410,0003,198,400413,858Nov 30 07:30 AM
DENNER ALEXANDER JDirectorNov 28Buy316.1220,0006,322,400403,858Nov 30 07:30 AM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 25Sale290.014,9741,442,51022,258Jul 26 04:22 PM
ALEXANDER SUSAN HEVP Chief Legal Corp Svc & SecJul 19Sale285.007,7582,211,03027,232Jul 20 05:00 PM
Posner Brian SDirectorJun 09Sale256.311,084277,8406,330Jun 12 04:29 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,25904,027Jun 05 04:38 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,73604,663May 04 04:16 PM
Vounatsos MichelChief Executive OfficerMay 01Buy271.351,402380,4332,927May 02 04:18 PM
DENNER ALEXANDER JDirectorApr 27Buy278.5073,85820,569,476383,858May 01 05:47 PM
Clancy Paul JExecutive VP and CFOApr 25Sale290.009,8922,868,68010,813Apr 27 04:23 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratApr 03Sale274.081,981542,9527,060Apr 04 04:18 PM
Clancy Paul JExecutive VP and CFOMar 13Sale291.559,8912,883,72120,705Mar 14 07:32 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.004810718Mar 03 06:07 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratMar 01Sale290.07973282,2389,041Mar 03 06:02 PM
Clancy Paul JExecutive VP and CFOFeb 28Option Exercise0.006,780031,948Mar 02 05:24 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 28Option Exercise0.004,785010,398Mar 02 05:22 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 28Option Exercise0.005,559036,024Mar 02 05:20 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 28Option Exercise0.0068104,508Mar 02 05:18 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffFeb 28Option Exercise0.002,06409,237Mar 02 05:16 PM
DiPietro KennethEVP Human ResourcesFeb 28Option Exercise0.005,69608,260Mar 02 05:12 PM
Vounatsos MichelChief Executive OfficerFeb 27Buy285.391,333380,4251,434Mar 01 04:18 PM